Hip Fracture Risk in Elderly Adults: Evaluating Prediction Tools

By Staff Writer

September 25, 2024

Introduction

Hip fractures are a significant concern for adults aged 80 and older, accounting for 70% of such injuries in the US. These fractures lead to severe consequences. Approximately 20% to 30% of fracture patients dying within a year and many survivors experiencing impaired mobility and disability. Given that hip fractures represent 72% of fracture-related healthcare expenditures in the US, identifying individuals at high risk is crucial. Researchers evaluated the effectiveness of the Fracture Risk Assessment Tool (FRAX) and the Garvan fracture risk calculator in predicting hip fractures in late-life adults. Their study focuses on the performance of these tools in a cohort of 8,890 community-dwelling adults aged 80 and older, followed for five years.

Understanding the Tools: FRAX and Garvan

Although the gradient of risk decreases with age, low bone mineral density (BMD) is a significant predictor of hip fracture. FRAX and Garvan are widely used tools that estimate a patient’s absolute risk of hip fracture. These tools incorporate femoral neck bone mineral density (FNBMD) and other clinical risk factors. However, their applicability in predicting hip fractures in adults aged 80 and older may be limited. Factors such as competing mortality risk and the prevalence of nonskeletal risk factors like frailty need to be considered.

The study found that both FRAX and Garvan tools incorporating FNBMD had fair to acceptable discrimination for predicting hip fractures over five years. Specifically, the area under the curve (AUC) for FRAX was 0.69 in women and 0.71 in men, while Garvan had an AUC of 0.69 in women and 0.76 in men. These values are lower than those reported for younger populations, indicating that the tools’ discriminative ability decreases with age.

Figure 1. Receiver Operating Characteristic Curves for Hip Fracture Prediction in Women and Men

Comparing Tool Performance

In their study, FRAX modestly underestimated hip fracture probability in intermediate-risk individuals, while Garvan markedly overpredicted it in high-risk individuals. The original FRAX derivation study reported a mean AUC of 0.78 for 10-year hip fracture prediction in a population with a mean age of 65 years. In contrast, the study’s AUC for 5-year prediction was lower, reflecting the challenges in predicting fractures in older adults.

Garvan’s performance was also suboptimal in the study. The original derivation study reported an AUC of 0.85 for both sexes in a younger Australian population. However, in the cohort of adults aged 80 and older, Garvan’s AUC was significantly lower. This discrepancy may be due to the model’s assumption that hip fracture hazards rise exponentially with age. However, this may not hold true for the oldest adults.

Clinical Implications

These findings show that FNBMD alone can discriminate hip fracture risk as effectively as the more complex FRAX and Garvan tools in adults aged 80 and older. A previous systematic review found that simple tools with fewer risk factors often match the performance of complex instruments in predicting osteoporotic fractures. In this study, lower FNBMD independently associated with hip fracture risk, even after considering competing mortality risk.

However, increasing age was not as strongly associated with hip fracture risk in late-life adults compared to younger older populations. This finding likely reflects the higher competing mortality risk before hip fracture in late life. Therefore, clinicians should consider hip BMD, life expectancy, and patient preferences when deciding on drug treatment for hip fracture prevention in late-life adults.

Conclusion

In this recent study of community-dwelling US adults aged 80 and older, FNBMD alone predicted 5-year hip fracture risk as well as the more complex FRAX and Garvan tools. FRAX modestly underestimated risk for intermediate-risk individuals. Garvan markedly overestimated risk for high-risk individuals. Until better prediction tools become available, clinicians should prioritise hip BMD, life expectancy, and patient preferences when making decisions about hip fracture prevention in late-life adults.

Reference url

Recent Posts

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

essential prescription drugs
       

Canada Launches Consultation for Essential Prescription Drugs List

💊 Are you curious about how Canada plans to make essential prescription drugs accessible for everyone?

Canada’s Drug Agency has launched a national consultation to create a list of essential prescriptions that aim to ensure equitable access, improve health outcomes, and reduce costs. This initiative marks a key step towards universal pharmacare and highlights the importance of evidence-based practices in healthcare.

Dive into our latest article to learn more about the implications for patients, policymakers, and the broader healthcare system!

#SyenzaNews #healthcare #HealthEconomics

ACIP vaccine policy concerns
     

ACIP Vaccine Policy Concerns

🛑 Is the future of vaccine policy at risk?

The recent overhaul of the US Advisory Committee on Immunization Practices (ACIP) raises critical concerns about the integrity and transparency in vaccine recommendations. The abrupt removal of longstanding members may disrupt the essential processes that have historically upheld public trust and immunization success.

Curious about the implications for health policy and public health? Dive into the full analysis to understand the balance needed between continuity and reform!

#SyenzaNews #HealthcarePolicy #HealthEconomics #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.